Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Receives $22.00 Average Target Price from Brokerages

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) has been given an average rating of “Buy” by the eleven analysts that are covering the company, reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $22.00.

Several equities analysts have issued reports on the company. Mizuho reissued a “buy” rating and issued a $28.00 price target on shares of Aerie Pharmaceuticals in a research note on Monday, December 28th. HC Wainwright restated a “buy” rating on shares of Aerie Pharmaceuticals in a report on Monday, March 1st. Finally, Needham & Company LLC started coverage on shares of Aerie Pharmaceuticals in a report on Friday, February 5th. They issued a “buy” rating and a $26.00 target price on the stock.

Shares of AERI stock opened at $18.04 on Monday. The company has a debt-to-equity ratio of 3.41, a quick ratio of 3.10 and a current ratio of 3.33. Aerie Pharmaceuticals has a fifty-two week low of $9.01 and a fifty-two week high of $21.30. The company has a market cap of $846.38 million, a PE ratio of -4.31 and a beta of 0.79. The stock’s fifty day moving average price is $18.40 and its two-hundred day moving average price is $14.51.

Aerie Pharmaceuticals (NASDAQ:AERI) last posted its earnings results on Thursday, February 25th. The company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.04). The company had revenue of $24.68 million during the quarter, compared to the consensus estimate of $21.75 million. Aerie Pharmaceuticals had a negative return on equity of 135.57% and a negative net margin of 231.05%. On average, equities analysts predict that Aerie Pharmaceuticals will post -3.76 EPS for the current fiscal year.

Institutional investors have recently added to or reduced their stakes in the stock. Schroder Investment Management Group lifted its position in shares of Aerie Pharmaceuticals by 22.5% during the fourth quarter. Schroder Investment Management Group now owns 1,402,975 shares of the company’s stock worth $18,954,000 after acquiring an additional 257,300 shares in the last quarter. Norges Bank purchased a new position in Aerie Pharmaceuticals during the 4th quarter valued at about $3,310,000. Pinnacle Associates Ltd. increased its position in shares of Aerie Pharmaceuticals by 42.4% during the fourth quarter. Pinnacle Associates Ltd. now owns 746,197 shares of the company’s stock valued at $10,081,000 after buying an additional 222,137 shares during the period. Voloridge Investment Management LLC lifted its holdings in shares of Aerie Pharmaceuticals by 103.4% in the third quarter. Voloridge Investment Management LLC now owns 205,170 shares of the company’s stock worth $2,415,000 after buying an additional 104,282 shares in the last quarter. Finally, DNB Asset Management AS bought a new position in shares of Aerie Pharmaceuticals in the fourth quarter valued at approximately $1,408,000. Institutional investors and hedge funds own 99.89% of the company’s stock.

Aerie Pharmaceuticals Company Profile

Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, ocular surface, and retinal diseases in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma.

Recommended Story: Dual Listing What You Need to Know

Analyst Recommendations for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with's FREE daily email newsletter.